Ann: Proposed issue of Securities - CAN, page-3

What are you on about?
The shares were issued to the CSIRO.

Shares issued pursuant to terms and conditions of a Share Purchase Agreement between CSIRO and the Company for services provided to the Company by CSIRO under a Research Services Agreement, during the quarter ending 31 December 2020.


Getting the green light for medicinal cannabis research
https://blog.csiro.au/getting-the-green-light-for-medicinal-cannabis-research/
We’ve teamed up with Cann Group to help them develop products that could be used to treat a range of conditions, including childhood epilepsy, chronic pain and loss of appetite in chemotherapy patients.

Cann Group is cultivating different strains of cannabis for medical use. Once our dedicated lab is fitted out, we will start analysing the crop for Cann Group to get a better idea of the cannabinoids present, their biological effects and how extracts could be manufactured.

While most research on medicinal cannabis has focussed on the effects of tetrahydrocannabinol (THC) and cannibidiol (CBD), we’re going to explore the minor cannabinoids and terpenes, which give the plant its characteristic smell.

From these results, we’ll begin developing various extracts with different chemical profiles tailored for certain conditions. It’s expected that these extracts will be taken as oral drops or inhaled as vapour.


Cann Group inks broad R&D agreement with CSIRO
https://www.australianmanufacturing.com.au/61105/cann-group-inks-broad-rd-agreement-with-csiro
Listed medicinal cannabis company Cann Group has inked a broad, multiyear agreement with CSIRO that extends the research and development collaboration between the two parties.

The new umbrella agreement will see Cann work with multiple CSIRO businesses to develop technologies for use in the commercial manufacture and sale of medicinal cannabis products.